Ajay Verma - 11 Nov 2021 Form 4 Insider Report for YUMANITY THERAPEUTICS, INC. (KANT)

Role
EVP, Head of R&D
Signature
/s/ Marie Epstein, Attorney-in-Fact
Issuer symbol
KANT
Transactions as of
11 Nov 2021
Net transactions value
$0
Form type
4
Filing time
15 Nov 2021, 07:00:16 UTC
Next filing
03 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KA Stock Option (Right to Buy) Award $0 +5,000 $0.000000 5,000 13 Apr 2021 Common Stock 5,000 $17.60 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 13, 2021, the reporting person was granted an option to purchase 20,000 shares of common stock, 5,000 shares of which vested and became exercisable upon certain performance criteria being met on November 11, 2021.